Literature DB >> 28730918

Clinical and economic implications of urinary tract infections.

Samantha N Steiger1, Rachel R Comito1, David P Nicolau2.   

Abstract

INTRODUCTION: Urinary tract infections represent one of the most frequent reasons for hospitalization. As a result of their prevalence from community-based origins as well as those which develop in hospital setting, this constellation of infections represents a tremendous burden to the global healthcare system. Areas covered: Over the last several decades the management of these infections has become more complicated due to the underlying comorbid conditions of the patients as well as escalating antimicrobial resistance to many of the most frequently used oral and parenteral agents. One such example is the emergence of extend spectrum β-lactamase-producing (ESBL) bacteria that render many of the most frequently utilized oral and parenteral penicillin and cephalosporin based regimens of little clinical utility. As such new treatment strategies are required to effectively manage the growing population of patients with multi-drug resistant bacteria. Expert commentary: Herein, we review some of the current literature which reveals the challenges associated with the contemporary management of UTIs, while presenting strategies such as the implementation of clinical pathways that have the potential to enhance the quality and efficiency of care while reducing the overall cost of care.

Entities:  

Keywords:  Urinary tract infection; antimicrobial resistance; clinical pathways; extended spectrum β-lactamases

Mesh:

Substances:

Year:  2017        PMID: 28730918     DOI: 10.1080/14737167.2017.1358618

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  7 in total

1.  Influence of primary care antibiotic prescribing on incidence rates of multidrug-resistant Gram-negative bacteria in hospitalised patients.

Authors:  Munther S Alnajjar; Mamoon A Aldeyab; Michael G Scott; Mary P Kearney; Glenda Fleming; Fiona Glimore; David Farren; James C McElnay
Journal:  Infection       Date:  2019-05-07       Impact factor: 3.553

2.  In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem.

Authors:  Nicole Cotroneo; Aileen Rubio; Ian A Critchley; Chris Pillar; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

3.  Microbiological Characterisation of Community-Acquired Urinary Tract Infections in Bagamoyo, Tanzania: A Prospective Study.

Authors:  Joseph Schmider; Nina Bühler; Hasina Mkwatta; Anna Lechleiter; Tarsis Mlaganile; Jürg Utzinger; Tutu Mzee; Theckla Kazimoto; Sören L Becker
Journal:  Trop Med Infect Dis       Date:  2022-06-12

4.  In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.

Authors:  Marguerite L Monogue; Sara Giovagnoli; Caterina Bissantz; Claudia Zampaloni; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  Clinical and Microbial Etiology Characteristics in Pediatric Urinary Tract Infection.

Authors:  Jiandong Lu; Xiaozhu Liu; Yi Wei; Chengjun Yu; Jie Zhao; Ling Wang; Yang Hu; Guanghui Wei; Shengde Wu
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.569

6.  Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment.

Authors:  James A Dowell; Thomas C Marbury; William B Smith; Tim Henkel
Journal:  Antimicrob Agents Chemother       Date:  2022-08-03       Impact factor: 5.938

7.  Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor.

Authors:  James A Dowell; Daniel Dickerson; Tim Henkel
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.